^(89)SrCL_2联合唑来膦酸治疗晚期肺癌骨转移瘤疼痛的临床应用价值  

^(89)SrCL_2 joint zoledronic acid treatment of advanced lung cancer bone metastases pain value of clinical application

作　　者：张长弓[1,2] 钱可宝[1,2] 李高峰[1,2] 叶联华[1,2] 向旭东[1,2] 陈楠[1,2] 

机构地区：[1]云南省肿瘤医院 [2]昆明医学院附属第三医院肺癌研究中心,650118

出　　处：《中国医疗前沿》2011年第19期64-65,共2页China Healthcare Innovation

摘　　要：目的观察89SrCL2联合唑来膦酸在治疗晚期肺癌多发性骨转移瘤、缓解重度骨痛、改善生活质量等方面的疗效。方法对35例晚期肺癌骨转移瘤中重度疼痛的患者分别用89SrCL2联合唑来膦酸治疗。结果 89SrCL2联合唑来膦酸联合治疗组有效率为91.4%。结论用89SrCL2联合唑来膦酸治疗转移性骨肿瘤,能显著减轻患者中重度疼痛、提高生活质量,是一种有效且较安全、可靠的方法。Objective To observe the 89SrCL2 joint zoledronic acid in the treatment of advanced lung cancer bone metastases,alleviate multiple severe bone pain,improve life quality,the effect of comparison.Methods Thirty-five patients with advanced cancer bone metastases moderate to severe pain patients respectively for 89SrCL2 joint zoledronic acid treatment.Results 89SrCL2 joint zoledronic acid combination therapy group,Effective rate was 91.4%.Conclusion 89SrCL2 joint zoledronic acid treatment metastatic bone tumors can significantly reduce pain patients with moderate to severe,improve the quality of life,it is a kind of effective and relatively safety and reliability of the method.

关 键 词：晚期肺癌 骨转移瘤 89SrCL2 唑来膦酸 疼痛 

分 类 号：R734.2[医药卫生—肿瘤]